The latest announcement is out from Mind Medicine ( (MNMD) ).
MindMed has begun dosing patients in Panorama, its second Phase 3 study of MM120 ODT for treating generalized anxiety disorder. The trial aims to evaluate the efficacy and safety of the proprietary LSD formulation in a 52-week study across the US and Europe, seeking to address significant unmet needs in psychiatry with potentially transformative treatments.
More about Mind Medicine
Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company that focuses on developing novel product candidates to treat brain health disorders.
YTD Price Performance: -2.92%
Average Trading Volume: 1,506,521
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $544.9M
For detailed information about MNMD stock, go to TipRanks’ Stock Analysis page.